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and pre-NMAT platelets < 25k/uL (33% vs 8%, p ¼ 0.01). In an
unadjusted comparison, OS and PFS favored the RIT pts, but
the differences were not statistically signiﬁcant (hazard ratio
[HR] for OS ¼ 0.60, 95% conﬁdence interval [CI]: 0.3-1.4, p ¼
0.24; HR for PFS ¼ 0.75, 95% CI: 0.4-1.5, p ¼ 0.41). However,
after adjusting for signiﬁcant differences between these
groups, outcomes for the RIT-treated group were signiﬁcantly
better (HR for OS¼ 0.30; 95% CI: 0.1-0.8, p¼ 0.007; HR for PFS
¼ 0.42, 95% CI: 0.2-0.9, p ¼ 0.02). With a median follow-up of
81months in surviving patients, the 3-year adjusted estimates
for the RIT and control groups were: OS 87% and 59%, PFS 71%
and 44%, respectively (Figures 1 and 2).
Conclusions: These data suggest that the addition of 90Y-
ibritumomab tiuxetan prior to NMATmay result in improved
OS and PFS for patients with persistent iB-NHL. These results
set the stage for a prospective randomized comparison of
these strategies in this setting.
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Introduction: Many patients with high-risk lymphoma
will experience relapse after autologous stem cell trans-
plantation (AutoSCT). There are no therapies given to pa-
tients in remission after AutoSCT which are of proven
beneﬁt. At time of disease relapse after AutoSCT, patients
are often considered for allogeneic stem cell trans-
plantation (AlloSCT) if remission can be achieved by salvage
strategies.
Methods: We conducted a phase II clinical trial of tandem
AutoSCT followed by reduced intensity conditioning (RIC)
AlloSCT for patients with high-risk lymphoma. High-dose
chemotherapy was BuCyE: busulfan (11.2 mg/kg IV total),
cyclophosphamide (120 mg/kg IV total), and etoposide (30
mg/kg IV total). RIC AlloSCT was performed any time be-
tween 40 days and 6 months after AutoSCT if disease had not
progressed. RIC was busulfan (3.2 mg/kg IV total) with ﬂu-
darabine (120 mg/kg IV total) with GVHD prophylaxis
comprised of tacrolimus, sirolimus, and methotrexate.
Results: A total of 42 patients were enrolled. All patients
had at least a partial remission to their last therapy. Eligible
patients in the up-front setting included T-cell lymphoma,
mantle cell lymphoma, and B-cell lymphoma with concur-
rent c-MYC and BCL-2 overexpression or translocations.
Other histologies were required to be relapsed / refractory
as deﬁned by number of lines of therapy or remission
duration < 12 months. All patients underwent BuCyE
AutoSCT. RIC AlloSCT was performed in 29 patients, 16 from
a matched related donor and 13 from a matched unrelated
donor. RIC AlloSCT was not performed in 13 patients
because of patient choice (n¼4), lack of a suitably matched
donor (n¼2), disease progression (n¼6), and therapy-
related AML (n¼1). There has been no transplant-related
mortality from AutoSCT. Of the 29 patients who underwent
both HSCT procedures, median time from AutoSCT to
AlloSCT was 96 days (range 48-169). All patients engrafted
successfully with day 100 median donor chimerism being
95% (range 85-99). The 6-month cumulative incidence of
grades II-IV acute GVHD was 7% (95% CI, 0.3%, 20%). Cu-
mulative incidence of chronic GVHD at one year was 36%
(17%, 56%). Non-relapse mortality at one year was 4.6%
(0.3%, 20%) with one death from sepsis. Cumulative inci-
dence of disease relapse was 20% (9%, 33%) for the entire
group and 8% (1%, 23%) for patients after AlloSCT. At a me-
dian follow-up after 15.9 months (range, 3.5-36.5) after
AutoSCT for the entire group, 1-yr progression-free survival
was 77% (60%, 87%) and 1-yr overall survival was 87% (72%,
95%). For the 28 survivors after AlloSCT, median follow-up is
11.8 months (range, 0.2-33.6), 1-yr PFS is 87% (66%, 96%) and
1-yr OS is 95% (72%, 99%).
Conclusion: Busulfan based tandem AutoSCT followed by
RIC AlloSCT appears safe and effective in patients with high-
risk lymphoma. Prospective trials comparing such a strategy
to either AutoSCT or RIC AlloSCT alone in speciﬁc lymphoma
subtypes are warranted.
